Fulvestrant and male breast cancer: a pooled analysis
- 18 December 2014
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 149 (1) , 269-275
Abstract
Male breast cancer is an uncommon malignancy; little is known regarding hormonal manipulations for tamoxifen-resistant male breast cancer patients. This is the first pooled analysis of the literature to synthesize all available data and to evaluate the efficacy and safety of fulvestrant in male breast cancer. This study was performed in accordance with the PRISMA guidelines. All studies that examined the efficacy of fulvestrant in male breast cancer, regardless of sample size, were considered eligible. The search strategy retrieved 31 articles; of these, five articles were eligible (23 patients) for this pooled analysis. The mean age of the study sample was 63.1 years. Adjuvant hormonal treatment was administered in 87.5 % of cases. Fulvestrant was given as first or second line in 40 % of patients, while as third line or beyond in 60 % of patients. 79.0 % of patients at fulvestrant administration had visceral metastases. Regarding best response, in 26.1 % PR was achieved, in 47.8 % of cases SD was recorded, whereas in 26.1 % of patients PD was noted. The median PFS was equal to 5 months. No grade 3 and 4 adverse events were recorded; of note, hot flashes were reported in 18.2 % of male breast cancer patients. Fulvestrant may potentially play a promising role in the optimal therapeutic strategy for male patients with breast cancer diagnosis. However, further clinical and pharmacokinetic investigations are more than warranted before fulvestrant use becomes a common practice in male breast cancer patients.Keywords
This publication has 24 references indexed in Scilit:
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)The Breast, 2014
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)Annals of Oncology, 2014
- Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM TrialJNCI: Journal of the National Cancer Institute, 2013
- Fulvestrant and male breast cancer: a case seriesAnnals of Oncology, 2013
- A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancerBreast Cancer Research and Treatment, 2011
- Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast CancerClinical Cancer Research, 2011
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaborationJournal of Clinical Epidemiology, 2009
- Prospective Evaluation of Risk Factors for Male Breast CancerJNCI: Journal of the National Cancer Institute, 2008
- Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECTJournal of Clinical Oncology, 2008
- Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivationThe Journal of Steroid Biochemistry and Molecular Biology, 2002